Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions

Area of Science:

• Hepatology
• Biomedical Engineering
• Critical Care Medicine

Background:

• Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) present significant clinical challenges with limited therapeutic options beyond liver transplantation (LT).
• LT is often limited by donor organ scarcity and patient eligibility, highlighting the need for alternative liver support strategies.
• Artificial extracorporeal blood purification systems aim to restore impaired liver function by enhancing toxin elimination and managing complications of liver decompensation.

Purpose of the Study:

• To review popular extracorporporeal blood purification techniques for liver replacement therapy.
• To discuss the principles of function and evidence regarding the effectiveness of these systems in detoxification for ALF and ACLF patients.
• To outline the advantages and disadvantages of current artificial liver support systems.

Main Methods:

• Review of existing literature on extracorporporeal blood purification techniques for liver failure.
• Analysis of the principles behind various detoxification methods used in artificial liver support systems.
• Evaluation of evidence on the efficacy of these systems in supporting patients with ALF and ACLF.

Main Results:

• Extracorporeal blood purification systems enhance the elimination of accumulated metabolites and inflammatory molecules in liver failure.
• Current systems often combine multiple methods to address different ranges of toxins, but extracting high-molecular-weight and hydrophobic molecules remains challenging.
• Conventional methods like plasma exchange are being re-evaluated, and novel adsorption filters show promise, yet no single optimal system has been developed.

Conclusions:

• Artificial extracorporeal blood purification systems are promising for treating liver failure but cannot fully replace liver function.
• Further research, including randomized controlled trials and meta-analyses, is crucial to understand the impact of these systems on patient survival.
• Development of improved artificial liver support systems is needed, with current options offering supportive but not definitive solutions for ALF and ACLF.